# Joseph A. Sparano

Source: https://onco.cc/people/joseph-sparano/  
OnCo record `joseph-sparano` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led TAILORx, which showed most women with intermediate Oncotype scores can safely skip chemotherapy.

## Summary

Joseph Sparano was study chair of TAILORx, the ECOG-ACRIN trial of 10,000 women that showed endocrine therapy alone is non-inferior to chemo-endocrine therapy for HR-positive, node-negative breast cancer with a mid-range 21-gene recurrence score. The result spared tens of thousands of patients chemotherapy each year and made genomic assays standard in early breast cancer. He continues to lead ECOG-ACRIN breast trials on treatment de-escalation and ctDNA.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: breast; de-escalation; ecog-acrin
- Role: Chief, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai
- Specialisms: Early breast cancer; Genomic assays; Chemotherapy de-escalation; Cooperative-group trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Sparano%20JA%5BAuthor%5D%20TAILORx

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- technologies: [Companion diagnostics](https://onco.cc/technologies/companion-diagnostic/)
- drugs: [Oncotype DX](https://onco.cc/drugs/oncotype-dx/)
- institutions: [The Mount Sinai Hospital / Tisch Cancer Institute](https://onco.cc/institutions/mount-sinai/)
- trials: [TAILORx](https://onco.cc/trials/tailorx/)

---
JSON: https://onco.cc/api/v1/entities/joseph-sparano.json